BENITIONSClinical Trial Intelligence

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

2상 완료 NCT04232280

대상 질환Cytomegalovirus Infection
임상 단계2상
스폰서ModernaTX, Inc.
상태완료
참여자 수315 명
중재(약물)mRNA-1647
시작일2020년 1월 9일
완료일2023년 1월 4일
결과 공개일2026년 5월 5일

요약

This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.

Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

Up to Day 175 (7 days following last dose administration) · Participants

Seronegative mRNA-1647 (50 ug)33 Participants
Seronegative mRNA-1647 (100 ug)59 Participants
Seronegative mRNA-1647 (150 ug)40 Participants
Seronegative Placebo12 Participants
Seropositive mRNA-1647 (50 ug)15 Participants
Seropositive mRNA-1647 (100 ug)33 Participants

Number of Participants With Unsolicited Adverse Events (AEs)

Up to Day 196 (28 days following last dose administration) · Participants

Seronegative mRNA-1647 (50 ug)16 Participants
Seronegative mRNA-1647 (100 ug)31 Participants
Seronegative mRNA-1647 (150 ug)18 Participants
Seronegative Placebo21 Participants
Seropositive mRNA-1647 (50 ug)10 Participants
Seropositive mRNA-1647 (100 ug)16 Participants

Number of Participants With Medically Attended Adverse Events (MAAEs)

Up to Day 336 (6 months following last dose administration) · Participants

Seronegative mRNA-1647 (50 ug)13 Participants
Seronegative mRNA-1647 (100 ug)24 Participants
Seronegative mRNA-1647 (150 ug)14 Participants
Seronegative Placebo19 Participants
Seropositive mRNA-1647 (50 ug)5 Participants
Seropositive mRNA-1647 (100 ug)11 Participants

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

전체 임상

이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.